The Cairo-Bishop criteria calculator is a tool used to assess the presence of clinical tumor lysis syndrome (TLS) by analyzing specific laboratory and clinical parameters. It helps determine if the diagnostic criteria for TLS are met by evaluating combinations of biochemical changes and clinical manifestations typically associated with the condition.

The laboratory criteria involve several key metabolic markers:
- Uric acid: ≥ 476 mcmol/L or a 25% increase from baseline
- Potassium: ≥ 6.0 mmol/L or a 25% increase from baseline
- Phosphate: ≥ 2.1 mmol/L in children or ≥ 1.45 mmol/L in adults or a 25% increase from baseline
- Calcium: ≤ 1.75 mmol/L or a 25% decrease from baseline

The clinical criteria focus on significant health impacts:
- Serum creatinine: ≥ 1.5 times the upper limit of normal
- Cardiac arrhythmias or sudden death
- Seizures

To establish a diagnosis for TLS, the calculator checks for combinations of these criteria. Specifically, the criteria are met if any two laboratory disturbances (from the choices above) are found to align with any clinical sign. An example would be elevated uric acid and potassium levels combined with a raised serum creatinine level or the occurrence of cardiac arrhythmias or seizures.

This structured approach ensures that all relevant parameters are considered, aiding healthcare providers in diagnosing TLS in patients potentially at risk. By using this calculator, clinicians can make informed decisions, potentially improving patient outcomes through timely intervention in cases of suspected tumor lysis syndrome.

The Cairo-Bishop criteria is a clinical calculator used to diagnose tumor lysis syndrome (TLS). This scoring system is applicable to patients with malignancies, particularly those with high-grade lymphomas and acute leukemias, who are at risk of developing TLS. The Cairo-Bishop criteria is clinically useful in identifying patients who have developed TLS, either spontaneously or following cancer treatment, by assessing changes in specific laboratory values including uric acid, potassium, phosphorus, and calcium levels. This calculator aids in risk stratification, guiding treatment decisions, and predicting prognosis. It does not have specific exclusion criteria, but it may be less applicable or accurate in patients with pre-existing electrolyte abnormalities or renal dysfunction not related to TLS.

Cairo-Bishop criteria for clinical tumor lysis syndrome